“…Treatment with 5-HT agents normalizes many of the neuroendocrine abnormalities (Holsboer, 1999;Holsboer and Barden, 1996;Keck and Holsboer, 2001;Maes et al, 1995;Nemeroff and Owens, 2004;Rybakowski and Twardowska, 1999;Weizman et al, 1988), and the response to 5-HT has been used as a marker of clinical improvement following drug treatment (Bhagwagar et al, 2002;Raap and Van de Kar, 1999). Data from our laboratory have shown altered physiological and behavioral responses to the 5-HT 1A agonist 8-OH-DPAT (Hofmann et al, 2002) as well as an increase in anxiety-like behavior and anxiolytic responses to 8-OH-DPAT in E compared with control animals (Hofmann et al, 2005). Together with the present data showing that E animals have altered ACTH responses to 5-HT agonists and 5-HT 1A receptor mRNA expression, these findings suggest that E animals have altered 5-HT-HPA interactions, and/or an imbalance between 5-HT 1A and 5-HT 2A receptor function (Lanfumey et al, 2000;Zhang et al, 2005).…”